ArticleBMC complementary medicine and therapies2025
Shugan Xiaozhi Decoction attenuates nonalcoholic steatohepatitis by modulating oxidative stress and AMPK pathway.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD), particularly the histological phenotype nonalcoholic steatohepatitis (NASH), is considered the primary cause of chronic liver diseases. Shugan Xiaozhi decoction (SX), a composite Chinese medicinal formula, has shown therapeutic potential for NASH, although the underlying mechanisms remain incompletely defined. In this study, the effects and mechanisms of SX in rats with NASH and fibrosis induced by a high-fat and high-cholesterol (HFHC) diet were investigated.
methodsNASH rats with fibrosis were induced by an HFHC diet, with different doses of SX administered. Biochemical indices, histological changes, and gene expression were assessed to evaluate lipid metabolism, inflammation, fibrosis of the liver. The histological changes of white and brown adipose tissue were also determined. Hepatic transcriptomics and network pharmacology based on the blood components were employed to elucidate the biological processes and signaling pathways, which was subsequently verified, and the material basis of SX was investigated through docking simulations.
resultsSX treatment effectively corrected disordered lipid profiles, mitigated hepatic phagocyte infiltration, and alleviated damage in the white and brown adipose tissues. It also downregulated the expression of NLRP3, caspase-1, IL-1β, α-SMA, Col1a1, and TGF-β, to improve hepatic inflammation and fibrosis. Mechanistically, transcriptomics and network pharmacology analyses revealed that SX ameliorated hepatic oxidative stress and activated the AMPK pathway, and the downstream effector Nrf2 and inactivated of SREBP1/FAS signaling. Three putative phytochemicals, namely, gallic acid, protocatechuic acid, and rhein with the highest binding affinity for AMPKα were also identified.
conclusionsSX ameliorates HFHC diet-induced NASH by regulating hepatic oxidative stress and AMPK pathway, suggesting the potential therapeutic value of SX in NASH treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.